Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Evaluation of sericin as a fetal bovine serum-replacing cryoprotectant during freezing of human mesenchymal stromal cells and human osteoblast-like cells

M. Verdanova, R. Pytlik, MH. Kalbacova,

. 2014 ; 12 (2) : 99-105.

Language English Country United States

Document type Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't

Grant support
NT13531 MZ0 CEP Register

A reliable, cryoprotective, xeno-free medium suitable for different cell types is highly desirable in regenerative medicine. There is danger of infection or allergic reaction with the use of fetal bovine serum (FBS), making it problematic for medical applications. The aim of the present study was to develop an FBS-free cryoprotective medium for human mesenchymal stromal cells (hMSCs; primary cells) and immortalized human osteoblasts (SAOS-2 cell line). Furthermore, we endeavored to eliminate or reduce the presence of dimethyl sulfoxide (DMSO) in the medium. Sericin, a sticky protein derived from the silkworm cocoon, was investigated as a substitute for FBS and DMSO in the freezing medium. Cell viability (24 hours after thawing, both hMSC and SAOS-2) and colony-forming ability (2 weeks after thawing, only for hMSCs) were both determined. The FBS-free medium with 1% sericin in 10% DMSO was found to be a suitable freezing medium for primary hMSCs, in contrast to immortalized human osteoblasts. Surprisingly, the storage of hMSCs in a cultivation medium with only 10% DMSO also provided satisfactory results. Any drop in DMSO concentration led to significantly worse survival of cells, with little improvement in hMSC survival in the presence of sericin. Thus, sericin may substitute for FBS in the freezing medium for primary hMSCs, but cannot substitute for DMSO.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15008095
003      
CZ-PrNML
005      
20190514110348.0
007      
ta
008      
150306s2014 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1089/bio.2013.0078 $2 doi
035    __
$a (PubMed)24749876
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Verdánova, Martina $u 1 Institute of Inherited Metabolic Disorders, Faculty of Science, Charles University in Prague , Prague, Czech Republic .
245    10
$a Evaluation of sericin as a fetal bovine serum-replacing cryoprotectant during freezing of human mesenchymal stromal cells and human osteoblast-like cells / $c M. Verdanova, R. Pytlik, MH. Kalbacova,
520    9_
$a A reliable, cryoprotective, xeno-free medium suitable for different cell types is highly desirable in regenerative medicine. There is danger of infection or allergic reaction with the use of fetal bovine serum (FBS), making it problematic for medical applications. The aim of the present study was to develop an FBS-free cryoprotective medium for human mesenchymal stromal cells (hMSCs; primary cells) and immortalized human osteoblasts (SAOS-2 cell line). Furthermore, we endeavored to eliminate or reduce the presence of dimethyl sulfoxide (DMSO) in the medium. Sericin, a sticky protein derived from the silkworm cocoon, was investigated as a substitute for FBS and DMSO in the freezing medium. Cell viability (24 hours after thawing, both hMSC and SAOS-2) and colony-forming ability (2 weeks after thawing, only for hMSCs) were both determined. The FBS-free medium with 1% sericin in 10% DMSO was found to be a suitable freezing medium for primary hMSCs, in contrast to immortalized human osteoblasts. Surprisingly, the storage of hMSCs in a cultivation medium with only 10% DMSO also provided satisfactory results. Any drop in DMSO concentration led to significantly worse survival of cells, with little improvement in hMSC survival in the presence of sericin. Thus, sericin may substitute for FBS in the freezing medium for primary hMSCs, but cannot substitute for DMSO.
650    _2
$a zvířata $7 D000818
650    _2
$a skot $7 D002417
650    _2
$a viabilita buněk $x účinky léků $7 D002470
650    _2
$a kryoprezervace $x metody $7 D015925
650    _2
$a kryoprotektivní látky $x chemie $x farmakologie $7 D003451
650    _2
$a kultivační média bez séra $x chemie $x farmakologie $7 D016895
650    _2
$a dimethylsulfoxid $x chemie $x farmakologie $7 D004121
650    _2
$a zmrazování $7 D005615
650    _2
$a lidé $7 D006801
650    _2
$a mezenchymální kmenové buňky $x cytologie $7 D059630
650    _2
$a osteoblasty $x cytologie $7 D010006
650    _2
$a sericiny $x chemie $x farmakologie $7 D047030
650    _2
$a sérum $x chemie $7 D044967
655    _2
$a hodnotící studie $7 D023362
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Pytlík, Robert, $d 1967- $7 xx0061345
700    1_
$a Kalbacova, Marie Hubalek
773    0_
$w MED00186149 $t Biopreservation and biobanking $x 1947-5543 $g Roč. 12, č. 2 (2014), s. 99-105
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24749876 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150306 $b ABA008
991    __
$a 20190514110453 $b ABA008
999    __
$a ok $b bmc $g 1065368 $s 890895
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 12 $c 2 $d 99-105 $i 1947-5543 $m Biopreservation and biobanking $n Biopreserv Biobank $x MED00186149
GRA    __
$a NT13531 $p MZ0
LZP    __
$a Pubmed-20150306

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...